Principal Investigator
Overview
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT02685826
Status
Closed for Recruitment
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Sarah MacEwan, Research Coordinator
Phone
Email Address
Purpose of Study
This is a multicenter, open-label, Phase 1/2 study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with Newly diagnosed multiple myeloma (NDMM).
The study will consist of a dose-finding phase as well as a parallel dose-expansion phase to determine the optimal regimen
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT02685826
Status
Closed for Recruitment
Start/End Dates
Locations
Vancouver General Hospital
Name/Title
Sarah MacEwan, Research Coordinator
Phone
Email Address
Purpose of Study
This is a multicenter, open-label, Phase 1/2 study to determine the recommended dose and regimen of durvalumab in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subjects with Newly diagnosed multiple myeloma (NDMM).
The study will consist of a dose-finding phase as well as a parallel dose-expansion phase to determine the optimal regimen
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.
